The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis

Harris, C. A., Ward, R. L., Dobbins, T. A., Drew, A. K. and Pearson, S. (2011) The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of Oncology, 22 6: 1308-1317. doi:10.1093/annonc/mdq593

Author Harris, C. A.
Ward, R. L.
Dobbins, T. A.
Drew, A. K.
Pearson, S.
Title The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
Journal name Annals of Oncology   Check publisher's open access policy
ISSN 0923-7534
Publication date 2011-06-01
Year available 2010
Sub-type Article (original research)
DOI 10.1093/annonc/mdq593
Open Access Status Not yet assessed
Volume 22
Issue 6
Start page 1308
End page 1317
Total pages 10
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Language eng
Formatted abstract
Background: The addition of HER2-targeted agents to standard treatment has been shown to improve outcomes for HER2 positive metastatic breast cancer patients. We undertook a meta-analysis to evaluate the efficacy of HER2-targeted therapy in addition to standard treatment in metastatic breast cancer patients.

Patients and methods: Eligible trials were randomised controlled trials (RCTs) comparing the addition of HER2 therapy to standard treatment (hormone or chemotherapy) reporting overall survival (OS), time to progression (TTP), progression-free survival (PFS) and/or response rates.

Results: Eight trials comprising 1848 patients were eligible for inclusion. HER2-targeted agents were trastuzumab and lapatinib and therapeutic partners were taxanes (4 RCTs), anthracyclines (1), capecitabine (2), anastrozole (1) and letrozole (1). The addition of HER2-targeted agents improved OS [hazard ratios (HR) 0.78; 95% confidence interval (CI) 0.67-0.91], TTP (HR 0.56; 95% CI 0.48-0.64), PFS (HR 0.63; 95% CI 0.53-0.74) and overall response rate (relative risk 1.67; 95% CI 1.46-1.90).

Conclusions: Our meta-analysis confirms the benefit of adding HER2-targeted therapy to standard treatment in HER2 positive metastatic breast cancer. Compared with OS, TTP, PFS and ORR overestimate treatment benefit. Trials in our meta-analysis differed in terms of partner drug or HER2 agents, yet delivered comparable outcomes.
Keyword Chemotherapy
HER2 positive
Hormone therapy
Metastatic breast cancer
Targeted therapies
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID 568921
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 43 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 45 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 10 Feb 2015, 23:54:06 EST by Ms Kate Rowe on behalf of Learning and Research Services (UQ Library)